Welcome to our dedicated page for Ufp Technologies news (Ticker: UFPT), a resource for investors and traders seeking the latest updates and insights on Ufp Technologies stock.
UFP Technologies, Inc. (UFPT) is a Nasdaq-listed contract development and manufacturing organization focused on single-use and single-patient medical devices. Its news flow centers on financial performance, strategic acquisitions, facility expansions, leadership updates, and investor outreach, all within the context of the medical device and advanced manufacturing sectors.
Investors following UFPT news can expect regular earnings releases detailing quarterly and year-to-date results, including net sales, profitability metrics, and non-GAAP measures such as organic sales growth, adjusted operating income, adjusted net income, and adjusted EBITDA. These releases are typically accompanied by conference call announcements and webcast information, giving additional context on trends in the company’s MedTech and non-medical businesses, gross margins, and SG&A spending.
Company news also highlights strategic moves such as the acquisitions of Universal Plastics & Engineering Company, Inc. (UNIPEC) and Techno Plastics Industries, Inc. (TPI), which expand UFP Technologies’ capabilities in tight-tolerance film components and thermoplastic molding for the medical device market. Updates on expansion projects in locations such as Santiago and La Romana in the Dominican Republic, and commentary on programs in safe patient handling and robotic-assisted surgery drape solutions, appear in these communications.
In addition, UFPT issues press releases about participation in investor conferences, updated investor presentation materials, and governance developments such as its CEO succession plan. The UFPT news page aggregates these items so readers can review financial updates, acquisition announcements, operational developments, and leadership changes in one place.
UFP Technologies (Nasdaq: UFPT) will present and host 1x1 investor meetings at the Raymond James 47th Annual Institutional Investors Conference in Orlando, March 1-4, 2026. Chairman & CEO R. Jeffrey Bailly and CFO Ron Lataille will present on March 3, 2026 at 2:50 PM ET. A live webcast of the presentation will be available.
UFP Technologies (Nasdaq: UFPT) reported record 2025 results: net sales $602.8M (+19.5% YoY), net income $68.3M (+15.8% YoY) and GAAP EPS $8.75. Medical sales rose 23.2% to $555.3M while non-medical fell 11.5% to $47.5M. Adjusted EBITDA was $121.1M.
The company noted AJR labor inefficiencies cost ~$6.3M in 2025, easing to $1.2M in Q4, and highlighted facility expansion and contract extensions in the Dominican Republic plus recent acquisitions integrating into operations.
UFP Technologies (Nasdaq: UFPT) will report fourth quarter and year-end 2025 results on February 24, 2026 after market close and host a conference call on February 25, 2026 at 8:30 AM ET.
Investors may join via the provided toll-free numbers or a live webcast; a replay will be available on the company’s Investor Relations website.
UFP Technologies (Nasdaq: UFPT) announced a planned CEO succession: R. Jeffrey Bailly will retire as CEO at the company’s next annual meeting on June 4, 2026. At that time, President Mitchell Rock will become CEO and join the Board, while Bailly will serve as Executive Chairman for one year to facilitate the transition.
The release notes Bailly’s 31-year tenure, company expansion to operations in five countries, a workforce of nearly 5,000 associates, and historical growth of about 20-fold revenue and >150-fold profitability and market capitalization under his leadership.
UFP Technologies (Nasdaq: UFPT) announced that Chairman & CEO R. Jeffrey Bailly, President Mitchell C. Rock, and CFO Ron Lataille will present and host 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference in New York City, December 1-4, 2025.
UFP's presentation is scheduled for 8:10 AM ET on Wednesday, December 3, 2025, and a live audio webcast of the presentation will be available.
UFP Technologies (Nasdaq: UFPT) reported Q3 2025 net income of $16.4M or $2.11 diluted EPS, matching Q3 2024, and adjusted EPS of $2.39. Q3 sales were $154.6M (+6.5% YoY) and nine-month sales were $453.9M (+26.0% YoY). Nine-month net income was $50.7M versus $42.6M year‑ago. Medical market sales strengthened (+31.1% YTD). The company cited $3M incremental labor costs at its Illinois AJR facility and > $8M of unfulfilled Q3 orders tied to that issue. Management highlighted DR facility ramp, robotic surgery program launches, and two recent acquisitions performing ahead of expectations.
UFP Technologies (Nasdaq: UFPT) will report third-quarter 2025 financial results on Monday, November 3, 2025 after market close. A conference call to discuss results is scheduled for Tuesday, November 4, 2025 at 8:30 AM Eastern. Participants can join by the listed toll-free dial-ins for USA/Canada and international numbers, or listen via a live webcast. A replay of the webcast and accompanying materials will be available on the company’s Investor Relations website at https://ufpt.com/investors/.
UFP Technologies (NASDAQ:UFPT) announced its participation in the upcoming 16th Annual Midwest IDEAS Investor Conference. President Mitch Rock and CFO Ron Lataille will deliver a presentation on August 26, 2025, at 7:55 AM CT at The InterContinental in Chicago, IL.
Investors can access the presentation through the conference website at threepartadvisors.com/midwest or via UFP's investor relations section at ufpt.com.
UFP Technologies (Nasdaq: UFPT) reported outstanding Q2 2025 results with significant growth across key metrics. Net income reached $17.2 million ($2.21 per diluted share), up from $13.6 million in Q2 2024. Sales surged 37.2% to $151.2 million, driven by acquisitions and 5% organic growth.
The company's MedTech business grew 46% while Advanced Components declined 20%. During Q2, UFPT completed two strategic acquisitions: Universal Plastics & Engineering (UNIPEC) and Techno Plastics Industries (TPI), enhancing capabilities in specialty film components and medical device thermoplastic molding. Despite facing $1.2 million in temporary labor costs at the AJR facility, gross margins remained strong at 28.8%.
Year-to-date performance showed continued strength with sales up 39.1% to $299.3 million and adjusted EBITDA increasing 39.1% to $62.1 million.
UFP Technologies (NASDAQ: UFPT), a contract development and manufacturing organization focused on medical devices, will release its second quarter 2025 financial results on August 4, 2025 after market close.
The company will host a conference call to discuss the results on August 5, 2025, at 8:30 AM ET. Investors can access the call via toll-free (1-888-243-4451) or international (1-412-542-4135) numbers. A live webcast and accompanying materials will be available at www.ufpt.com, with a replay accessible afterward on the company's Investor Relations website.